"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
Descriptor ID |
D007004
|
MeSH Number(s) |
D27.505.696.422
|
Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
1996 | 0 | 1 | 1 |
1997 | 1 | 1 | 2 |
1998 | 1 | 0 | 1 |
1999 | 2 | 3 | 5 |
2000 | 1 | 1 | 2 |
2001 | 1 | 1 | 2 |
2002 | 0 | 6 | 6 |
2003 | 5 | 3 | 8 |
2004 | 7 | 4 | 11 |
2005 | 5 | 5 | 10 |
2006 | 4 | 3 | 7 |
2007 | 7 | 3 | 10 |
2008 | 5 | 4 | 9 |
2009 | 11 | 4 | 15 |
2010 | 18 | 9 | 27 |
2011 | 17 | 9 | 26 |
2012 | 14 | 7 | 21 |
2013 | 10 | 8 | 18 |
2014 | 16 | 6 | 22 |
2015 | 10 | 5 | 15 |
2016 | 13 | 12 | 25 |
2017 | 13 | 9 | 22 |
2018 | 7 | 9 | 16 |
2019 | 8 | 11 | 19 |
2020 | 11 | 8 | 19 |
2021 | 7 | 13 | 20 |
2022 | 1 | 14 | 15 |
2023 | 0 | 8 | 8 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
In adults with overweight or obesity and CVD, but without diabetes, semaglutide reduced MACE at a mean 40 mo. Ann Intern Med. 2024 Mar; 177(3):JC31.
-
Emerging evidence for glucagon-like peptide-1 agonists in slowing chronic kidney disease progression. Curr Opin Nephrol Hypertens. 2024 May 01; 33(3):331-336.
-
Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2024 Jan; 26(1):11-23.
-
Editorial: Global excellence in natural products for endocrine disorders. Front Endocrinol (Lausanne). 2023; 14:1325355.
-
Addendum. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S41-S48. Diabetes Care. 2023 09 01; 46(9):1716-1717.
-
What are we waiting for? A review of early basal insulin therapy in diabetic ketoacidosis management. Am J Emerg Med. 2023 10; 72:147-150.
-
Baseline leptin predicts response to metformin in adolescents with type 1 diabetes and increased body mass index. Diabetes Obes Metab. 2023 11; 25(11):3420-3423.
-
Continuous Glucose Monitoring versus Standard of Care in Adolescents With Type 2 Diabetes: A Pilot Randomized Cross-Over Trial. J Diabetes Sci Technol. 2023 09; 17(5):1419-1420.
-
A Retrospective Cohort Analysis of Two Computerized Insulin Infusion Protocols. J Diabetes Sci Technol. 2023 05; 17(3):635-641.
-
Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocr Rev. 2023 03 04; 44(2):254-280.